Previous Article | Next Article ![]()
Molecular and Cellular Biology, January 2000, p. 104-112, Vol. 20, No. 1
Department of Biological Chemistry and
Molecular Pharmacology, Harvard Medical School, Boston,
Massachusetts 021151; Department of
Molecular Biology and Microbiology, Tufts University School of
Medicine, Boston, Massachusetts 021112; and
Department of Biochemistry, Duke University Medical Center,
Durham, North Carolina 277103
Received 9 July 1999/Returned for modification 25 August
1999/Accepted 8 October 1999
The cotranscriptional placement of the 7-methylguanosine cap on
pre-mRNA is mediated by recruitment of capping enzyme to the phosphorylated carboxy-terminal domain (CTD) of RNA polymerase II.
Immunoblotting suggests that the capping enzyme guanylyltransferase (Ceg1) is stabilized in vivo by its interaction with the CTD and that
serine 5, the major site of phosphorylation within the CTD heptamer
consensus YSPTSPS, is particularly important. We sought to identify the
CTD kinase responsible for capping enzyme targeting. The candidate
kinases Kin28-Ccl1, CTDK1, and Srb10-Srb11 can each phosphorylate a
glutathione S-transferase-CTD fusion protein such that
capping enzyme can bind in vitro. However, kin28 mutant
alleles cause reduced Ceg1 levels in vivo and exhibit genetic
interactions with a mutant ceg1 allele, while
srb10 or ctk1 deletions do not. Therefore, only the TFIIH-associated CTD kinase Kin28 appears necessary for proper capping enzyme targeting in vivo.
Interestingly, levels of the polyadenylation factor Pta1 are also
reduced in kin28 mutants, while several other
polyadenylation factors remain stable. Pta1 in yeast extracts binds
specifically to the phosphorylated CTD, suggesting that this
interaction may mediate coupling of polyadenylation and transcription.
0270-7306/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Kin28, the TFIIH-Associated Carboxy-Terminal Domain Kinase,
Facilitates the Recruitment of mRNA Processing Machinery to RNA
Polymerase II
*
Corresponding author. Mailing address: Department of
Biological Chemistry and Molecular Pharmacology, Harvard Medical
School, Boston, MA 02115. Phone: (617) 432-0696. Fax: (617) 738-0516. E-mail: steveb{at}hms.harvard.edu.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|